The EUA only needs to show potential benefit, not proven benefit, compared to it's safety profile so it shouldn't matter if the trial was under powered. The trial showed strong potential benefit in the severe to critical elderly population (ya know, the people who were dying the most) with a very low risk associated with the drug. Based on the criteria for EUA we should have been granted that status. We would have lost it once the pandemic was over earlier this year but the amount of money we had earned could have funded more trials in other indications. Instead, we got screwed and so did, potentially, a lot of elderly people who died of COVID.